Laura González-Lafuente Selected Research

Cinnamates

1/2015

New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura González-Lafuente Research Topics

Disease

3	Acute Kidney Injury (Acute Renal Failure) 12/2023 - 01/2022
3	Cardiomegaly (Heart Hypertrophy) 09/2022 - 01/2021
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2016 - 09/2013
3	Brain Ischemia (Cerebral Ischemia) 12/2015 - 01/2011
3	Neuroblastoma 01/2011 - 08/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2022
2	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 09/2013
2	Infarction (Infarctions) 12/2015 - 09/2013
2	Vascular Diseases (Vascular Disease) 01/2011 - 08/2010
1	Necrosis 12/2023
1	Renal Insufficiency (Renal Failure) 12/2023
1	Cardio-Renal Syndrome 09/2022
1	Inflammation (Inflammations) 09/2022
1	Reperfusion Injury 02/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Long QT Syndrome 01/2022
1	Uremia 01/2022
1	Fibrosis (Cirrhosis) 01/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2020
1	Stroke (Strokes) 12/2015
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2015
1	Neuroinflammatory Diseases 01/2015
1	Memory Disorders (Memory Loss) 09/2013
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2011

Drug/Important Bio-Agent (IBA)

5	CalciumIBA 12/2023 - 01/2022
3	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 12/2023 - 01/2022
3	AntioxidantsIBA 12/2015 - 01/2011
3	MelatoninIBA 12/2015 - 09/2013
3	Neuroprotective AgentsIBA 12/2015 - 01/2011
3	oligomycin AIBA 01/2011 - 08/2010
3	RotenoneIBA 01/2011 - 08/2010
2	MineralsIBA 01/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 01/2015
2	Cholinergic Agents (Cholinergics)IBA 01/2011 - 08/2010
1	phospholambanIBA 01/2022
1	Fibroblast Growth Factor-23IBA 01/2022
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2022
1	Phosphorus (Red Phosphorus)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Spironolactone (Aldactone)FDA LinkGeneric 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2022
1	Troponin T (Troponin T1)IBA 01/2022
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021
1	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2020
1	pro-brain natriuretic peptide (1-76)IBA 12/2020
1	oxidized low density lipoproteinIBA 12/2020
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2016
1	gramineIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2015
1	Glucose (Dextrose)FDA LinkGeneric 12/2015
1	Oxygen (Dioxygen)IBA 12/2015
1	Melatonin Receptors (Melatonin Receptor)IBA 12/2015
1	N- (2- (5- methoxy- indol- 3- yl)- ethyl)- 4- oxo- 4H- pyran- 2- carboxamideIBA 12/2015
1	Glutamic Acid (Glutamate)FDA Link 12/2015
1	MT2 Melatonin ReceptorIBA 12/2015
1	CinnamatesIBA 01/2015
1	Galantamine (Galanthamine)FDA LinkGeneric 09/2013
1	Scopolamine (Hyoscine)FDA Link 09/2013
1	ethyl 5- amino- 2- methyl- 6,7,8,9- tetrahydrobenzo(b)(1,8)naphthyridine- 3- carboxylateIBA 09/2013
1	Muscarinic AntagonistsIBA 09/2013
1	LigandsIBA 09/2013
1	nitronesIBA 01/2011
1	Tacrine (Cognex)FDA Link 01/2011
1	compound 17IBA 08/2010